# Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

> **NCT02216513** · EARLY_PHASE1 · TERMINATED · sponsor: **Brigham and Women's Hospital** · enrollment: 2 (actual)

## Conditions studied

- Subarachnoid Hemorrhage

## Interventions

- **DRUG:** desferrioxamine (DFO)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02216513
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2015-06
- **Final completion:** 2015-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Principle Investigator is moving to another institution and plans to restart this proctocol in the new location.
- **Last updated:** 2015-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02216513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02216513, "Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02216513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*